AcelRx Pharmaceuticals, Inc. (ACRX)
| Market Cap | 123.63M |
| Revenue (ttm) | 5.42M |
| Net Income (ttm) | -40.38M |
| Shares Out | 85.26M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $1.03 |
| Previous Close | $1.07 |
| Change ($) | -0.04 |
| Change (%) | -3.74% |
| Day's Open | 1.07 |
| Day's Range | 1.02 - 1.09 |
| Day's Volume | 1,852,221 |
| 52-Week Range | 1.01 - 2.94 |
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced a poster presentation at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting reviewing the results of a study on the intraoperative...
HAYWARD, Calif., May 13, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative th...
HAYWARD, Calif., May 10, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after ...
HAYWARD, Calif., May 6, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative ther...
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced an investigator-initiated study to assess the perioperative use of Dsuvia (sufentanil sublingual tablet) for same-day surgical procedures in patie...
REDWOOD CITY, Calif., April 8, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovati...
REDWOOD CITY, Calif., March 31, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therap...
REDWOOD CITY, Calif., March 25, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therap...
New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such inve...
NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advi...
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 16.67% and -1.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 44.44% year over year to ($0.10), which were ...
REDWOOD CITY, Calif., March 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovat...
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advi...
AcelRx Pharmaceuticals and Sundial Growers could both be poised for a major growth spurt.
REDWOOD CITY, Calif., March 8, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter financial results...
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The company announced the pricing of a public stock offering.
REDWOOD CITY, Calif., Jan. 19, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovativ...
Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.
REDWOOD CITY, Calif., Dec. 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapi...
REDWOOD CITY, Calif., Dec. 9, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...
REDWOOD CITY, Calif., Dec. 4, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...
Acelrx shares plummeted after the company released third quarter earnings. However, numbers were significantly up compared to any prior period.
REDWOOD CITY, Calif., Nov. 6, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q3 2020 Results - Earnings Call Transcript
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -42.86% and -77.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the st...
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AcelRx (ACRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.
REDWOOD CITY, Calif., Sept. 29, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovat...
REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 19, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
ACRX Shareholders had a lot to digest during the past three months, including capital raise, cancelled and new marketing agreements, and the exit from the Tetraphase bidding war.
AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2020 Results - Earnings Call Transcript
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 42.86% and -25.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
REDWOOD CITY, Calif., Aug. 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif., June 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative...
REDWOOD CITY, Calif., June 1, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...
AcelRx Pharmaceuticals: Finally Light At The End Of The Tunnel
AcelRx Pharmaceuticals: Lean Back And Watch The Rocket Launch
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q1 2020 Results - Earnings Call Transcript
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -33.33% and -85.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
About ACRX
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Feb 14, 2011 |
| CEO Vincent Angotti | Employees 54 |
| Stock Exchange NASDAQ | Ticker Symbol ACRX |
Financial Performance
In 2020, ACRX's revenue was $5.42 million, an increase of 136.61% compared to the previous year's $2.29 million. Losses were -$40.38 million, -24.16% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for ACRX stock is "Buy." The 12-month stock price forecast is 6.67, which is an increase of 547.57% from the latest price.